

## HAT-field: a very cheap, robust and quantitative point-of-care serological test for Covid-19.

Etienne Joly<sup>1\*</sup> and Agnès Maurel Ribes<sup>2</sup>

1 : Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, 31000, France

2 : Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Toulouse, 31000, Toulouse, France

\*: correspondence to EJ: [atnjoly@mac.com](mailto:atnjoly@mac.com)

### Abstract

We have recently described a very simple and cheap serological test called HAT to detect antibodies directed against the RBD of the SARS-Cov-2 virus. HAT is based on hemagglutination, triggered by a single reagent (IH4-RBD) comprised of the viral RBD domain fused to a nanobody specific for glycoporphin, which is expressed at very high levels at the surface of human red blood cells (RBCs).

One of the main initial goals of this study was to devise a test protocol that would be sensitive and reliable, yet require no specialized laboratory equipment such as adjustable pipets, so that it could be performed in the most remote corners of the world by people with minimal levels of training. Because antibody levels against the viral RBD have been found to correlate closely with sero-neutralisation titers, and thus with protection against reinfection, it has become obvious during the course of this study that making this test reliably quantitative would be a further significant advantage.

We have found that, in PBN, a buffer which contains BSA and sodium azide, IH4-RBD is stable for over 6 months at room temperature, and that PBN also improves HAT performance compared to using straight PBS. We also show that performing HAT at either 4°C, room temperature or 37°C has minimal influence on the results, and that quantitative evaluation of the levels of antibodies directed against the SARS-CoV-2 RBD can be achieved in a single step using titration of the IH4-RBD reagent.

The HAT-field protocol described here requires only very simple disposable equipment and a few microliters of whole blood, such as can be obtained by finger prick. Because it is based on a single soluble reagent, the test can be adapted very simply and rapidly to detect antibodies against variants of the SARS-CoV-2, or conceivably against different pathogens. HAT-field appears well suited to provide quantitative assessments of the serological protection of populations as well as individuals, and given its very low cost, the stability of the IH4-RBD reagent in the adapted buffer, and the simplicity of the procedure, could be deployed pretty much anywhere, including in the poorest countries and the most remote corners of the globe.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 47 **Introduction**

48 For the past two years, the Covid-19 pandemic has preoccupied the whole world, and it  
49 remains a major concern for all nations, albeit with different perspectives depending on  
50 their wealth. In affluent nations, most people have now been vaccinated, and the main  
51 issues now are when to start offering booster vaccinations and to whom. Poorer countries,  
52 by contrast, have had limited access to vaccines or even to diagnostic tests simply to follow  
53 the progress of the pandemic within their populations. For both affluent and less affluent  
54 countries, access to a robust and reliably quantitative point-of-care (PoC) serological test  
55 would be a great asset to tackle these problems. Such a test would allow health  
56 professionals, and health authorities, to distinguish people with either no or waning levels of  
57 antibodies, who should have priority for vaccination or re-vaccination, from those with high  
58 levels of antibodies against the SARS-CoV-2 virus, who may not need to be vaccinated or  
59 revaccinated immediately, and may actually be the ones most likely to suffer undesirable  
60 effects from vaccine injections.

61  
62 Last year, we described a very simple, inexpensive serological test for Covid-19 called the  
63 HAT (hemagglutination test; (Townsend et al. 2021). HAT uses a recombinant protein (IH4-  
64 RBD) comprised of a nanobody, IH4, which binds to human glycoprotein at the surface of red  
65 blood cells (Habib et al. 2013), fused to the receptor-binding domain (RBD) of the SARS-CoV-  
66 2 virus. When mixed with diluted human blood, this reagent coats the red blood cells (RBCs)  
67 and, if antibodies to the viral RBD domain are present in the blood sample, they will cause  
68 hemagglutination. This test thus detects specifically antibodies against the RBD, which  
69 means that it can be used as a surrogate sero-neutralization test since those antibodies are  
70 the main ones endowed with sero-neutralizing activity against the virus (Ertesvåg et al. 2021;  
71 Jeewandara, Kamaladasa, et al. 2021; Lamikanra et al. 2021). Another important feature of  
72 HAT is that, because it is based on a soluble reagent, it can be adapted very easily and  
73 rapidly to detect antibodies against different variant forms of the virus (Ertesvåg et al. 2021;  
74 Jeewandara, Kamaladasa, et al. 2021) or presumably to other pathogens if needed be, for  
75 example in the context of a newly arising pathogen.

76  
77 In the format initially described for HAT, quantitative evaluation of the levels of antibodies  
78 was possible via serial dilutions of serum or plasma before mixing with washed autologous  
79 RBCs, or obtained from O- donors (Townsend et al. 2021). In this simple single-point format,  
80 HAT was recently used to measure seropositivity rates in Sri Lanka and compared well to a  
81 sensitive ELISA (Jeewandara, Guruge, et al. 2021). Here, we describe an adapted protocol,  
82 called HAT-field, which is quantitative through titration of the IH4-RBD reagent and can be  
83 performed in a single simple step with no specialized equipment. The observation that the  
84 performances of the assay are minimally affected by temperatures and that, in the  
85 optimized HAT-field buffer, which contains BSA and azide, the reagent is stable for weeks  
86 with no refrigeration required could also greatly facilitate the use of HAT-field in remote  
87 locations.

88  
89


90 **Results**

91 **BSA prevents adsorption of IH4-RBD to the reaction wells**

92 Following the method originally described by Wegmann and Smithies (Wegmann and  
93 Smithies 1966), the original HAT protocol uses 96 conical-well plates (Townsend et al. 2021).  
94 When appropriately diluted blood is mixed with the IH4-RBD reagent in these conical wells,  
95 the RBCs sediment during the incubation of 60 minutes; hemagglutination due to specific  
96 antibodies against RBD in the blood is observed by the formation of persistent ‘buttons’ of  
97 RBCs in the bottom of the well when the plate is tilted, whereas in the absence of  
98 hemagglutination a ‘teardrop’ shape forms (Townsend et al. 2021).

99  
100 To perform HAT in field conditions and/or on large numbers of samples, it would be much  
101 simpler for the users to be provided with the IH4-RBD reagent already distributed in the V-  
102 well plates used to perform the HAT tests. The plates, however, are made of polystyrene, to  
103 which many proteins tend to adsorb. (This non-specific adsorption is the basis for many  
104 ELISA tests; (Kenny and Dunsmoor 1983). Indeed, when the IH4-RBD reagent was diluted in  
105 PBS and placed in the wells, some of it was readily adsorbing to the plastic of the wells’  
106 slopes, and causing the formation of diffuse veils in hemagglutinated wells, which not only  
107 raised concerns about losing some of the active reagent by its immobilization on the plastic,  
108 but could make the reading of the results of the HAT tests less clear than the formation of  
109 bright red buttons (Figure 1A). Furthermore, in preliminary experiments involving serial  
110 dilutions of the IH4-RBD reagent, we found that the diluted IH4-RBD reagent tended to be  
111 lost rapidly through this phenomenon of adsorption.

112  
113 We solved this problem of veil formation by diluting the IH4-RBD reagent in PBN (Figure 1A,  
114 right columns of each panel), which is PBS containing 1% BSA and 3mM sodium azide, to  
115 prevent contamination by micro-organisms. In PBN, rather than veils, buttons of  
116 hemagglutination were observed and could be distinguished easily from the teardrops in the  
117 negative controls. These buttons formed whether the RBCs, which were added after the IH4-  
118 RBD reagent, were resuspended in PBS, in PBS supplemented with 1% plasma from the same  
119 seronegative donor as the RBCs, or in PBN. We conclude from this experiment that veil  
120 formation is due to adsorption of the IH4-RBD reagent to the polystyrene walls of the wells.  
121 This interpretation is supported by our finding that no veils formed when the wells were  
122 precoated with BSA and rinsed with PBS before performing the assay (Figure 1B).



123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136


**Figure 1: BSA prevents adsorption of IH4-RBD to the reaction wells.**

- A) HAT was performed in uncoated wells prefilled with IH4-RBD reagent diluted in either PBS (left columns) or PBS + 1% BSA + 3mM sodium azide (PBN, right columns). RBCs, resuspended in either PBS (left panels), in PBS supplemented with 1% seronegative autologous plasma (middle panels), or PBN (right panels) and various antibodies against SARS-CoV-2 were added to each well to test for hemagglutination. In the absence of antibody (Neg) the typical teardrop structure can be seen in each well. In the presence of a monoclonal antibody against RBD (CR3022), or plasma from convalescent Covid-19 patients, a veil structure forms in the absence of BSA, whereas a button forms when BSA is present. (see Methods for details)
- B) HAT as in (A) but performed in wells pre-coated with BSA. In the presence of the monoclonal antibody or convalescent patient plasma, hemagglutination is observed as a button rather than the veils seen in (A). Similar data were obtained from three experiments.

#### **Azide and BSA increase the sensitivity of HAT**

To investigate whether the presence of BSA and azide diminishes the performance of the HAT, we diluted the IH4-RBD reagent in PBS, in PBS containing 3mM sodium azide (PBS-N3), or in PBN and used these diluted reagents to test hemagglutination of whole blood and O-RBCs from a sero-negative donor resuspended in 1% plasma from the same donor, in the presence of various concentrations of the monoclonal anti-RBD CR3022 or various dilutions of an immune serum (Figure 2).

144



145  
146 **Figure 2: Azide and BSA increase the sensitivity of HAT**

- 147 A) The effects of azide and BSA on HAT performed using RBCs from a seronegative donor  
148 resuspended in PBS, PBS-N3 or PBN and 1% plasma from the same donor, or with whole blood  
149 from the same donor, and with various dilutions of an immune serum from a convalescent  
150 Covid-19 patient (Serum 197; left columns) or a monoclonal anti-RBD (CR3022; right columns).  
151 The three negative controls were: no antibody (0), neither antibody nor IH4-RBD, and the most  
152 concentrated serum or antibody condition with no IH4-RBD. Blue circles indicate the titration  
153 endpoints. (see Methods for details)
- 154 B) After HAT, the RBCs were resuspended, stained with a fluorescent secondary anti-human Ig  
155 antibody and analyzed by FACS. The numbers shown correspond to specific signals, i.e. the  
156 difference in GMFI values of each sample with that of the control sample incubated in the same  
157 buffer with no antibody or IH4-RBD. The squares highlighted in yellow indicate the titration  
158 endpoints.  
159 Similar data were obtained from four experiments.


160  
161 Rather than diminishing the performance of HAT, we found that the presence of azide  
162 improved its sensitivity: when HAT was performed in PBS-N3 rather than PBS, the titration  
163 endpoints (figure 2A, blue circles) were shifted by one double dilution (DD), and this  
164 occurred both with immune sera and with monoclonal antibodies. Addition of 1% BSA  
165 sometimes improved sensitivity by another DD, but we only saw this in some experiments,  
166 and not others.

167 To investigate the possible cause of the increased sensitivity of HAT in the presence of  
168 sodium azide, we used fluorescence-activated cell sorting (FACS) to analyze the amount of  
169 antibody bound to the RBCs at the end of the HAT. Dilution of the IH4-RBD reagent in PBS-  
170 N3 or in PBN resulted in a small increase in the amount of antibody bound to the surface of  
171 the RBCs, but not to an extent that would explain the increased sensitivity (Figure 2B). We  
172 postulate that the increased sensitivity due to the presence of azide may, instead, be due to  
173 an 'ageing' effect on the RBCs (see Discussion)

174  
175

176 **IH4-RBD is very stable when diluted in PBN**

177 For use in the field, it would be most convenient for the IH4-RBD reagent to be pre-  
 178 distributed in the wells, raising the question of the stability of working dilutions of the  
 179 reagent, both in the cold and at ambient temperatures. To investigate the stability of IH4-  
 180 RBD, we prepared aliquots of IH4-RBD at 2 µg/ml in either PBS-N3 or in PBN, on various  
 181 dates over the course of 15 months and stored those aliquots at 4°C, room temperature (RT)  
 182 or 37°C. Those IH4-RBD aliquots of various ages were then used to perform HAT titrations of  
 183 the reagent in the presence of constant amounts of the CR3022 monoclonal antibody (Figure  
 184 3). In some experiments, to evaluate more precisely the remaining activity of IH4-RBD after  
 185 incubation, we also quantified the amounts of antibodies bound to the surface of the RBCs  
 186 by using FACS (red numbers in Figure 3).  
 187



188 **Figure 3: IH4-RBD is very stable when diluted in PBN**

189 The effects of long-term storage of IH4-RBD in PBS-N3 or PBN at 4°C, RT and 37°C, as determined by  
 190 HAT and by FACS analysis of antibody binding to RBCs after HAT. Hemagglutination end-points in the  
 191 presence of the CR3022 monoclonal antibody at 100 ng/ml (black circles) were determined by  
 192 titration of aliquots of working dilutions of IH4-RBD stored for up to 15 months at the indicated  
 193 temperatures. The red numbers indicate the intensity of the specific fluorescent staining recorded by  
 194 FACS analysis performed after the HAT assay on the RBCs from the samples incubated with 100  
 195 ng/ml IH4-RBD (see Methods for details). Similar data were obtained in seven experiments, some of  
 196 which also included using diluted sera from convalescent patients in parallel to the CR3022  
 197 monoclonal antibody (not shown).  
 198

199  
 200 By performing such experiments repeatedly, we found that IH4-RBD is remarkably stable  
 201 when diluted in PBN: no significant loss of activity was seen for any of the IH4-RBD PBN  
 202 dilutions kept for over a year at 4°C, and this was true for up to 6 months at room  
 203 temperature. At 37°C, we did see some progressive loss of activity, but this only resulted in  
 204 the loss of one DD in HAT sensitivity at 9.5 months (after 15 months, evaporation had caused  
 205 the loss of what was left of the aliquots kept at 37°C).

206 On the other hand, the activity of IH4-RBD dilutions prepared in PBS-azide were usually  
 207 already lower by one DD than those prepared in PBN on day zero. Furthermore, we  
 208 observed marked variability over time between the IH4-RBD dilutions prepared in PBS-azide  
 209 on different dates: some batches showed a drop of just one DD compared to the dilutions  
 210 prepared in PBN, and stayed stable for many weeks after this; for others, however, we  
 211 witnessed much more marked losses over time, dropping to undetectable levels after just a

212 few weeks, even for tubes kept at 4°C. In retrospect, we suspect that this variability may be  
213 linked to the fact that, because the Covid-19 crisis had caused a penury of plasticware,  
214 different types and brands of plastic tubes had to be used to prepare and stock the IH4-RBD  
215 dilutions on different dates, and those different tubes probably had different protein-  
216 binding capacities, resulting in the variable loss of the diluted IH4-RBD protein.


217  
218 The important take-home message we draw from this set of experiments is that, regardless  
219 of the brand or type of plastic tubes used, as long as IH4-RBD was diluted in PBN, the activity  
220 of the diluted stocks was always remarkably reproducible, and stable for over a year if kept  
221 at 4°C, and with only marginal losses for dilutions kept at room temperature or 37°C. This  
222 remarkable stability of IH4-RBD, which is the sole reagent required for HAT, could greatly  
223 facilitate making this serological test available to populations living in remote environments,  
224 with no access to refrigeration.

225

### 226 **Temperature has little influence on HAT results**

227 For use as a PoC test in the field, the HAT should be robust in many environments and, in  
228 particular, at a broad range of temperatures. To evaluate how temperature influences the  
229 results of the HAT, we set-up three identical 96-wells plates for 2D titration experiments (i.e.  
230 double dilutions of antibodies in one direction, and of the IH4-RBD reagent in the other) and  
231 incubated those at three different temperatures: at 4°C (on ice in a cold room), at RT (*ca.*  
232 21°C), and at 37°C (in a CO<sub>2</sub> cell culture incubator; Figure 4).

233



234

### 235 **Figure 4: Temperature has little influence on HAT results**

236 To determine the effect of temperature on the performance of HAT, three parallel plates were setup  
237 for 2D titrations, with DD of IH4-RBD going from 8 µg/ml to 8 ng/ml along lines, and DD of two  
238 different immune sera from convalescent Covid-19 patients down columns (see Methods for  
239 practical details). After incubation at the indicated three temperatures, no substantial differences  
240 were seen in titration end-points (blue circles). Similar results were obtained in 3 independent  
241 experiments, using a total of 3 different immune sera, 2 plasmas, and the CR3022 monoclonal  
242 antibody.

243

244

245 Incubation temperature had little or no discernable influence on the hemagglutination  
246 endpoints (blue circles), with the possible exception of the wells containing the highest  
247 concentration of IH4-RBD and very diluted sera, where incubation at 4°C resulted in a small  
248 improvement in sensitivity when compared to the assays performed at RT or 37°C.

249  
250

### 251 **The HAT-field protocol**


252 The observation that, in 2D titrations such as those shown in Figure 4, the titration  
253 endpoints were distributed in an almost linear fashion on an X–Y axis suggested to us that a  
254 quantitative version of HAT might be developed by using dilutions of IH4-RBD rather than by  
255 using serial dilutions of plasma or sera and donor RBCs. We have now devised such a  
256 quantitative protocol, which only requires, for each test, one lancet, one plastic Pasteur  
257 pipet, one plastic tube containing 300 µl of PBS–2mM EDTA, 10 µl of whole blood, and one  
258 column of 8 conical wells on a 96-well plate, preloaded with 60 µl/well of a range of  
259 concentrations of IH4-RBD (Figure 5).

260

261 The lancet is used to express a lentil-size drop of capillary blood from a clean fingertip of the  
262 subject to be tested. The plastic Pasteur pipet is used to collect 10 µl of that blood, which  
263 corresponds to filling the first section of the pipet (the precise volume of blood collected is  
264 not critical; it may vary by as much as 30% with no detectable influence on the results). The  
265 blood is diluted *ca.* thirty-fold in the tube containing 300 µl of PBS - 2mM EDTA. The same  
266 pipet is then used to collect all 310 µl of this diluted blood and to transfer one drop into  
267 each of the 8 wells of a 96-well plate, prefilled with 60 µl of PBN containing 7 concentrations  
268 of IH4-RBD, and a negative control well containing either PBN or IH4 alone (not fused to  
269 RBD) diluted in PBN to a similar molar concentration as the highest IH4-RBD concentration  
270 used. As for the original HAT, the plate is incubated at room temperature, tilted after 60  
271 minutes, and photographed after *ca.* 20 seconds. The photograph will later be used to score  
272 the samples. Scoring simply corresponds to the number of fully hemagglutinated wells in a  
273 column, and thus goes from 0 (no hemagglutination in the well with the highest  
274 concentration of IH4-RBD, i.e. 3.16 µg/ml) to 7 (full hemagglutination in the well with the  
275 lowest concentration of IH4-RBD, i.e. 3.16 ng/ml). For the tilting and the photographing, we  
276 find it convenient to use a very simple home-made light box (see supplementary  
277 information) and a standard smart phone camera.

278





**Figure 5: Schematic description of the HAT-field protocol**

279  
280  
281  
282 One limitation of HAT is that it is not as sensitive as ELISA, CLIA (chemiluminescence  
283 immunoassay) or FACS (Maurel Ribes et al. 2021; Lamikanra et al. 2021). As we have seen  
284 above (Figure 4), increased sensitivity can be attained by the use of more IH4-RBD reagent,  
285 but we found that another way to increase HAT sensitivity was to perform prolonged  
286 incubations. After 5 hours, for example, we saw a very significant improvement in sensitivity,  
287 with the titration endpoints increasing for most samples by 2 or 3 dilution points when  
288 compared to those after 60 minutes, with fewer and fewer samples that were detected  
289 positively by FACS remaining below the threshold value of 1 for HAT-field (Figure S1, first  
290 line).

291  
292 Such long incubations are, however, not practical for a test intended for use in field settings.  
293 To overcome this problem, we found that centrifugation of the plates at 100g for 1 minute  
294 increased sensitivity to a level equivalent, or even slightly superior to that of incubating the  
295 plates for 5 hours. This centrifugation step, moreover, may be performed 15 minutes after  
296 distributing the diluted blood in the plate, with similar results to those obtained if the plates  
297 were centrifuged after 60 minutes incubation (Figure S1, second line). With access to the  
298 means to centrifuge the assay wells (which can be achieved in adapted salad-spinners, see  
299 Discussion), the HAT-field protocol can thus be completed in less than 30 minutes, which  
300 would be compatible with performing it in certain field settings, for example in the context  
301 of vaccination centers, to identify individuals with high levels of antibodies, who might not  
302 need to be vaccinated or re-vaccinated.

303  
304

### 305 Validation of the HAT-field protocol


306 To validate the performance of the HAT-field protocol, we used a panel of 60 EDTA whole-  
307 blood samples collected in early September from patients in the hematology department of  
308 Toulouse University hospital. The samples were picked randomly from clinical samples left  
309 over after the prescribed hematology analyses had been performed. At that time, over 85%  
310 of the adult population had been vaccinated in France, and we thus expected a large  
311 proportion of the samples to be seropositive against the S protein of SARS-CoV-2, albeit at  
312 various levels.

313

314 The results obtained by HAT-field on these 60 whole blood samples were compared with  
315 those obtained by testing the plasma from the same samples by using the original HAT  
316 protocol with donor RBCs (Townsend et al. 2021), and by using the FACS-based Jurkat-S&R-  
317 flow test (Maurel Ribes et al. 2021), which is very sensitive, quantitative, and allows  
318 isotyping of the antibodies reacting against the S protein (Figure 6).

319

320



321

### 322 Figure 6: Validation of the HAT-field protocol by comparison with laboratory tests

323 Sixty randomly selected blood samples were used to compare the results of the HAT-field protocol  
324 with those of HAT plasma titrations and the Jurkat-S&R-flow test (see Methods). The graphs show  
325 one-on-one comparisons of the results obtained with those three tests, as indicated, using the values  
326 obtained by centrifuging the plates after 15 minutes (for HAT-field), and after 60 minutes for plasma  
327 titrations. Pearson's correlation coefficients are indicated in the bottom right corners. The dotted  
328 line in the left graph indicates the position of the median, and those in the middle and right graphs  
329 indicate the threshold for positive samples in the Jurkat-S&R-flow. The two red dots in each graph  
330 correspond to two negative samples, which gave false-positive results in HAT due to their reactivity  
331 against the IH4 nanobody moiety of the reagent. The orange dots correspond to samples positive in  
332 the Jurkat-S&R-flow test that showed some reactivity against the IH4 nanobody alone, albeit with  
333 lower titers than against the IH4-RBD reagent. For the sample represented by an orange dot  
334 surrounded by a red circle on the right graph, the plasma titration against the nanobody alone was  
335 positive, but it led to only partial hemagglutination with the IH4-RBD reagent (for actual values, see  
336 sample 48 in data file).

337

338 The very good correlation between the results of all three tests validates that the HAT-field  
339 protocol can be used for quantitative assessment of the levels of antibodies contained in a  
340 whole-blood sample in a single step, without the sophisticated equipment needed for the  
341 Jurkat-S&R-flow test, and without needing to separate the RBCs from plasma or serum and  
342 having access to RBCs from an O- donor, as in the experiment using the original HAT to  
343 perform plasma titrations.

344

345

## 346 **HAT-field works with Delta-variant IH4-RBD**

347 Our IH4-RBD reagent was designed to present the RBD sequence of the original Wuhan  
348 variant (residues 340–538 of the S protein; (Townsend et al. 2021). At the time of our study,  
349 however, a large proportion of the SARS-CoV-2 viruses circulating in France belonged to the  
350 Delta variant lineage ([see epidemiological report here](#) ), which has two mutations in the RBD  
351 domain (L452R and T478K in the B.1.617.2 strain) (Ertesvåg et al. 2021; Jayathilaka et al.  
352 2021). We therefore wanted to compare the results obtained with the IH4-RBD-Wuhan  
353 reagent (used above) with a reagent that incorporates the two mutations in the Delta  
354 variant, IH4-RBD-Delta. We tested the 60 blood samples with the IH4-RBD-Wuhan and IH4-  
355 RBD-Delta reagents in both the HAT-field and original HAT plasma titration assays. For most  
356 samples, the scores obtained were one or two units higher when the Wuhan IH4-RBD  
357 reagent was used than those with the IH4-RBD-Delta reagent (Figure S3). This is consistent  
358 with a previous report that, in vaccinated people, HAT titers obtained with the IH4-RBD-  
359 Delta tend to be lower than with the IH4-RBD-Wuhan (Jayathilaka et al. 2021), and with the  
360 fact that, at the time of our study, most people in the French population had antibodies due  
361 to being vaccinated and not as a consequence of a previous infection by the SARS-CoV2 virus  
362 (retrospective analysis of clinical information on our cohort of 60 blood samples revealed  
363 that only three samples were from patients who had ever had a positive PCR test for SARS-  
364 CoV-2 (see data file and Figure S3).

365

366

## 367 **Discussion**

368 The aim of this project was to define a HAT protocol that could be used in the field. As such,  
369 the HAT-field protocol needed to work with satisfactory sensitivity on capillary blood, and to  
370 involve no specialized laboratory equipment such as adjustable pipets and disposable tips. In  
371 the course of our efforts, we discovered that i) the use of PBN results in markedly improved  
372 HAT robustness and sensitivity ii) HAT sensitivity is markedly improved by prolonged  
373 incubations (or by brief low-speed centrifugation), albeit with a parallel drop in specificity iii)  
374 quantification could be achieved by titrating the IH4-RBD reagent rather than the plasmas or  
375 sera. Incidentally, we realized recently that such an approach of titrating the RBC-binding  
376 reagent had been suggested previously for an HIV serodiagnostic test (Kemp et al. 1988).

377

378 PBN is a buffer containing both 1% BSA and azide, which has several concomitant  
379 advantages: i) Used as a dilution buffer for the IH4-RBD, it blocks the reagent's nonspecific  
380 adsorption to plastic, and results in its much improved stability over time, even if kept out of  
381 the cold. ii) The conjoint action of azide and BSA results in increased sensitivity, probably  
382 because they both improve the settling of the RBCs at the bottom of the wells. iii) In  
383 experiments which involve the use of O- RBCs, for example when using HAT to titrate  
384 plasmas or sera, the use of whole blood (or the addition of 1% seronegative plasma or  
385 serum) is no longer necessary when PBN is used to prepare a suspension of washed O- RBCs.  
386 We feel that this advantage is quite significant since most blood donors in the population  
387 have now become seropositive because of vaccinations.

388

389 As we have seen, the improvement of HAT sensitivity provided by prolonging incubations up  
390 to 5 hours can be very advantageously replaced by a brief step of centrifugation at 100g,  
391 which can be performed after only 15 minutes of incubation. The need for a centrifuge with  
392 the capacity to spin 96 well plates would, however, rather preclude the possibility of  
393 performing HAT in the field. But accelerations of 100g are in the range of those attained by

394 hand-driven centrifuges such as [salad spinners](#). We have investigated the possibility of using  
395 this type of centrifuge for spinning 96 well plates after just 15 to 20 minutes of incubation,  
396 but have found that this only works for the central 2 columns of a 96 well plate because the  
397 RBCs in the outer columns are pushed to the outside of the wells. Whilst it is hard to  
398 conceive that hand-driven centrifuges with the capacity to spin 96 well plates in swinging-  
399 out trays could become part of the equipment enabling the use of HAT in the field, a rather  
400 simple solution would be to design plastic strips of conical wells for individual tests. Using  
401 very simple adapters, those purposefully designed sets of wells could then be spun in hand-  
402 driven centrifuges of the salad spinner type. The design, and manufacture, of such  
403 disposable strips of wells, which would necessarily require the involvement of an industrial  
404 partner, was, however, well beyond the means of this study.  
405

406 One important consideration about performing centrifugation at the end of a HAT assay is  
407 that, whilst this works very well with RBCs contained in whole blood samples, or with  
408 washed RBCs from freshly collected blood, we found that it can become problematic with  
409 RBCs that have been stored at 4°C for more than a week. Over time, stored RBCs will indeed  
410 progressively lose their capacity to teardrop, which can, incidentally, result in a slight  
411 improvement of the apparent sensitivity of HAT assays performed under simple gravity.  
412 But, if submitted to accelerations of 100g, we have found that such “aged” RBCs will form  
413 compact pellets that will fail to teardrop, even upon prolonged tilting of the plate. (of note,  
414 this is also the case for RBCs that have been kept in azide for a few hours. Preparing  
415 suspensions of RBCs in PBN should thus be done just before performing the HAT assays).  
416

417 When performing HAT in PBN compared to PBS, we observed an increase in sensitivity which  
418 we suspect is most probably due to an improved sedimentation of the RBCs, with both azide,  
419 and BSA, contributing to the formation of more compact pellets at the bottom of the V-  
420 shaped wells. Regarding the role of azide, we postulate that, by blocking the metabolism of  
421 the RBCs, it probably increases their density and consequently their sedimentation.  
422 Regarding the beneficial role of facilitating the sedimentation of RBCs, this is something that  
423 Wegmann and Smithies had recognized soon after their initial description of the microtiter  
424 hemagglutination method, and for which they had proposed using paraffin-coated plates as  
425 an improvement (Wegmann and Smithies 1968). We feel, however, that the use of PBN as  
426 the diluting buffer of the IH4-RBD reagent is much simpler than that of paraffin-coated  
427 plates, and, as will be seen below, this has several other advantages, including the  
428 improvement of the stability of the reagent over time.  
429

430 Whilst HAT was, from its initial conception, always intended primarily to be carried out on  
431 capillary blood obtained by fingertip pricks, because of regulatory restrictions, all the  
432 experiments described in this paper had to be performed on samples of venous blood  
433 collected by phlebotomy. A recent study has shown that, as could be expected, HAT  
434 performed on capillary blood gives the same results as on venous blood samples (Ertesvåg et  
435 al. 2021), and preliminary results which we have obtained recently suggest that the results  
436 of the HAT-field protocol performed on capillary blood indeed correlate just as well with  
437 those of the Jurkat-S&R-flow test as those obtained with venous blood ( Joly et al., man. in  
438 prep.)  
439

440

441 In their original paper, Wegmann and Smithies had described using incubations of 4 to 6  
442 hours as their standard protocol, and suggested that a brief step of centrifugation could be  
443 used as an alternative (Wegmann and Smithies 1966). For the record, during the initial  
444 stages of this study, we had made several attempts to use centrifugation, but we did not  
445 have access to whole blood samples at the time. We were thus using O- RBCs which had  
446 often been stored at 4°C for up to several weeks, and had initially given up on centrifugation  
447 because the aged RBCs we were using failed to teardrop after centrifugation. Incidentally, in  
448 that same paper, Wegmann and Smithies also suggested using BSA as an alternative to  
449 serum or plasma to promote better RBC settling patterns. They were, however,  
450 recommending using BSA at 0.22% which we found to be less effective than 1% to block the  
451 adsorption of the IH4-RBD reagent to plastic.

452  
453 Once we had found that the use of centrifugation, combined to that of PBN as a buffer,  
454 could result in a marked improvement of the sensitivity of the ‘standard’ HAT assay in test  
455 samples, we needed to validate the performance of the modified HAT assay on clinical  
456 samples. For this, we made use of a cohort of 60 clinical blood samples of unknown  
457 serological status, and characterized those using the Jurkat-S&R-flow test, which is both  
458 extremely sensitive, quantitative, and allows the semi-quantitative isotyping of the plasmatic  
459 antibodies (Maurel Ribes et al. 2021). As seen on figure 6, we found very good correlations  
460 between all three tests: HAT-field, HAT plasma titrations, and the Jurkat-S&R-flow test.

461  
462 On the graph on the left of figure 6, which compares the scores of titrations by standard HAT  
463 to those obtained with HAT-field, most points are sitting above the median line, with several  
464 points (corresponding to 10 samples, see data file) not scoring positive by HAT-field (i.e. a  
465 score < 1) whilst being positive by standard HAT titration (i.e. score ≥ 1). In the conditions  
466 used in this study, the HAT-field protocol was thus markedly less sensitive than the  
467 optimized standard HAT approach, which can be explained by the conjunction of 4 factors:  
468 a) For titrations by standard HAT, we used plasmas at 1/50 as the highest concentration. In  
469 other words, we used 2 µl of plasma per well, to react against 0.3 µl of RBCs. The plasma to  
470 RBC ratio was thus six times more than in HAT-field, where there are roughly equivalent  
471 volumes of RBCs and plasma, and this ratio of 1 cannot be altered since, in HAT-field, the  
472 blood samples are simply diluted before performing the assay. On this subject, we have  
473 found that increasing the amount of whole blood per well (in other words using blood that is  
474 less dilute) has very little influence over the HAT-field results, and, if anything, adding more  
475 blood can sometimes reduce the sensitivity, albeit never by more than 1 dilution.  
476 b) Titrations for figure 6 were carried out on washed RBCs from an O- donor that were 5  
477 days old, and, in our hands, RBCs which have been washed and stored at 4°C for a few days  
478 tend to work a bit better for HAT than those in whole blood.  
479 c) When using washed RBCs, EDTA is no longer present, and we have found that excess EDTA  
480 can reduce HAT sensitivity for certain samples, possibly because the binding of certain  
481 antibodies may involve divalent cations. In the future, it may thus be interesting to explore  
482 the possibility of using heparin rather than EDTA as an anticoagulant.  
483 d) Whilst plasma titrations were carried out by double dilutions of the plasmas, in the  
484 optimized protocol we have devised for HAT-field, the IH4-RBD reagent is titrated in steps of  
485 3.16 fold, so as to cover a broader range (see Methods). This does, however, only really  
486 influence the upper right corner of the graph, i.e. the scores of samples with very high levels  
487 of antibodies.

488

489 On the right panel of figure 6, one finds four samples that scored positive by standard HAT,  
490 whilst the staining values in the Jurkat-S&R-flow test were in the doubtful zone between 10  
491 and 40, and our view is that those samples probably contained some antibodies reacting  
492 specifically against the SARS-CoV-2 spike protein, and their more effective detection by  
493 hemagglutination than by FACS staining may be due to relatively high proportions of IgAs or  
494 IgMs. This is indeed reminiscent of the observation reported in our first paper that HAT  
495 could detect antibody responses during very early SARS-CoV-2 infections before CLIA  
496 (Townsend et al. 2021). Incidentally, although this is not something that we have yet  
497 managed to document formally, we noticed that the samples which contain sizeable  
498 amounts of IgMs and/or IgAs often reach higher HAT scores than expected from the FACS  
499 results obtained with the pan-human Ig secondary antibody, with even higher scores by  
500 plasma dilutions than in HAT-field (see data file). Of note, for sample 19, which was a false  
501 positive and gave very high titers against that IH4 alone, FACS analysis performed after the  
502 HAT assay showed that the human antibodies bound to the IH4-coated RBCs were  
503 predominantly IgMs (data not shown).

504  
505 For one sample (n° 48 in data file), indicated by an orange symbol with a red circle in Figure  
506 6, the result of Jurkat-S&R-flow test was 44.84, i.e. just above the threshold value which is  
507 arbitrarily set to 40. This sample only led to partial hemagglutination at 1/50 in the standard  
508 HAT, but showed reactivity against the IH4 nanobody alone with an endpoint at 1/200 after  
509 centrifugation (score 3). We thus surmise that this sample does contains either very low or  
510 no specific anti-SARS-CoV-2 antibodies, which provides a justification for maintaining the  
511 Jurkat-S&R-flow test threshold at its current value.

512  
513 As in all biological tests, increasing the sensitivity will almost unavoidably lead to an increase  
514 in the proportion of false positives. It is thus not surprising that, with the gain of sensitivity  
515 of HAT afforded by the combined use of PBN and spinning, the proportion of samples being  
516 detected as showing some reactivity against the IH4 nanobody should be higher than the 1  
517 to 2% that were originally detected with the standard HAT protocol in various cohorts  
518 (Townsend et al. 2021; Maurel Ribes et al. 2021).

519  
520 In our current cohort, with the HAT-field protocol, reactivity against the IH4 moiety was  
521 detected in 3% of samples (2 out of 60) after one hour under normal gravity, and climbed to  
522 8 % (5 out of 60) after spinning. With the more sensitive protocol used for plasma titrations,  
523 5 samples (8%) reacted against the IH4 nanobody after one hour under simple gravity, but  
524 this number climbed to 12 (20% of samples) after spinning. If the HAT-field test was ever to  
525 be used in a clinical context, the results would be invalidated for those samples found to  
526 react with the IH4 alone, and with such high frequencies as we have observed in our small  
527 cohort, this could be a significant problem. An alternative would be to perform, from the  
528 start, systematic parallel titrations of the IH4-BRD and IH4 alone reagent, in order to identify  
529 samples which react markedly better on IH4-RBD than on IH4 alone. This could be achieved  
530 either by using 20 µl of blood diluted into 600 µl to distribute in two set of 8 wells, which  
531 would be quite easy since 20 µl corresponds to the second section on the plastic Pasteur  
532 pipets. Alternatively, titrations of the two reagents could be carried out over just 4 wells  
533 each, with larger dilution factors (e.g. 10 fold) between wells.

534  
535

536 In future, to reduce the proportion of false positives due to reactivities with the IH4 moiety,  
537 it may be interesting to investigate if the nanobody, which is of camel origin, could be  
538 somewhat “humanized” by site-directed mutagenesis without losing its capacity to bind to  
539 human glycoporphin. Alternatively, the use of different antibodies binding to glycoporphin,  
540 such as nanobodies derived from other species, or mAbs such as the one described by Kemp  
541 and colleagues (Kemp et al. 1988; Wilson et al. 1991) could also be explored as an  
542 alternative.

543  
544 Two recent reports have described that HAT could be performed on cards rather than in V-  
545 shaped wells, with semi-quantitative results being obtained in minutes, which was made  
546 possible by the use of much higher amounts of the IH4-RBD reagent than when HAT is  
547 performed in V-shaped well (Kruse et al. 2021; Redecke et al. 2021). Reliably quantitative  
548 card-based tests HAT test would unquestionably be a very attractive solution for performing  
549 the test in field settings. Comparing the sensitivity, specificity and robustness of the two  
550 types of protocols, on cards or in V-shaped wells, on the very same cohorts of whole blood  
551 samples would be very interesting, especially if such comparisons were performed by third  
552 party laboratories.

## 553 554 **Conclusion**

555 We have shown that the HAT-field approach, which uses a single drop of capillary blood, can  
556 provide in a single step, a quantitative measurement of the antibodies against the viral RBD,  
557 which are those endowed with neutralizing activity. Such a test could prove very useful for  
558 identifying individuals in need of a vaccine boost (or a primary injection). Given its very low  
559 cost, the stability of the IH4-RBD reagent, and the simplicity of the procedure, HAT-field  
560 should be well suited to be performed pretty much anywhere, including in the poorest  
561 countries and the most remote corners of the globe. Given that HAT has already been  
562 successfully adapted to detect antibodies against the RBD of several SARS-CoV2 variants  
563 (Ertesvåg et al. 2021; Jeewandara, Kamaladasa, et al. 2021), we presume that it could be  
564 adapted very rapidly to evaluate the levels of antibodies reacting against the RBD of other  
565 newly arising SARS-CoV2 variants of concern, such as the newly arisen and very divergent  
566 Omicron variant, or, in future, to pretty much any new threatening pathogen, and thus be  
567 better prepared to face future pandemics.

## 568 569 570 **Methods**

### 571 **Reagents**

572 PBS and tissue culture media were all obtained from Gibco.

573  
574 BSA Fraction V was obtained from Sigma (ref A8022 or A7888). Of note, we have tried using  
575 other sources of Fraction V BSA for preparing PBN, and found that they do not all work as  
576 well as the ones listed above to prevent veil formation in HAT.

577  
578 Sodium azide (NaN<sub>3</sub>, Sigma S2002) was prepared as a 20% stock solution in milli-Q water  
579 and kept at room temperature. This 3M solution was then used as a 1000x stock for the  
580 preparation of PBN, PFN and PBS-azide.

581  
582 PBN was prepared by adding 500 µl of the above 1000x Azide stock and 5 grams of BSA  
583 Fraction V (Sigma A8022) to 500 ml of PBS.

584  
585 PFN, used for the dilution of antibodies and washes of FACS samples, was prepared by  
586 adding 500 µl of the above 1000x azide stock and 10 ml of fetal calf serum to 500 ml of PBS  
587 (we find that this is a very good use for unwanted or expired stocks FCS that often clutter the  
588 bottom of freezers)  
589  
590 Because they contain azide (final concentration 3mM), no sterilizing filtration is needed for  
591 either PBN or PFN, and they can be kept for many weeks at 4°C.  
592  
593 Polyclonal anti-human Igs secondary antibodies, all conjugated to Alexa-488, were from  
594 Jackson laboratories, and purchased from Ozyme (France) . Refs: anti-human Ig-GAM: 109-  
595 545-064, -G: 109-545-003, -A: 109-54-011, -M: 109-545-129  
596  
597 Anti RBD monoclonal antibodies: CR3022 (ter Meulen et al. 2006) and EY6A (Zhou et al.  
598 2020) were obtained using antibody-expression plasmids, as previously described  
599 (Townsend et al. 2021).  
600  
601 Covid-19 sera 186, 197 and 203 were obtained from the virology department of the  
602 Toulouse hospital; plasmas 79 and 206 were from whole blood samples used in our previous  
603 paper describing the Jurkat-S&R-flow test (Maurel Ribes et al. 2021)  
604  
605 IH4-RBD (Wuhan and Delta) and IH4 alone were produced by transient transfection of HEK-  
606 293T cells, and purified from the supernatant by HIS-tag affinity purification, as previously  
607 described (Townsend et al. 2021). Highly concentrated stock solutions at 3 – 5 mg/ml in PBS  
608 were kept frozen as aliquots. Those were then used to prepare 100X stocks in either PBS or  
609 PBN, which were kept frozen, and kept a 4°C after thawing for up to a few weeks.  
610  
611 To study the stability of the IH4-RBD reagent over time, working solutions at 2 µg/ml in  
612 either PBS-azide or in PBN were prepared from 100X PBS stocks at various time points over  
613 the course of a whole year. Three aliquots of 500 µl each were then set aside from those  
614 working stocks, to be kept either at 4°C, at room temperature or at 37°C in a tissue culture  
615 incubator. The activity of those aliquots of working stocks was then evaluated at regular  
616 intervals by performing titrations of the IH4-RBD reagent against either the CR3022  
617 monoclonal antibody diluted to a final concentration of 100 ng/ml, or various immune sera  
618 diluted to give similar endpoint to those obtained with CR3022.  
619  
620 When comparing the reactivities against the Wuhan and Delta IH4-RBD reagents, we  
621 ascertained that we were using working concentrations of the two reagents with  
622 comparable activities by performing titrations with two monoclonals, EY6A or CR3022, which  
623 recognize a binding site not affected by the two mutations carried by the RBD of the Delta  
624 viral lineage, and found the Wuhan and Delta reagents to have indistinguishable  
625 hemagglutinating activities under those conditions.  
626  
627



628 **Ethical statement**

629 RBCs from O- blood donors were obtained from the Toulouse branch of the Etablissement  
630 Français du Sang (EFS), with whom the project was validated under agreement n°  
631 21PLER2020-025.

632  
633 Whole blood samples: The 60 samples used for figures 6 , S1, S2 and S3 were routine care  
634 residues from patients of the Toulouse hospital, where all patients give, by default, their  
635 consent for any biological material left over to be used for research purposes after all the  
636 clinical tests requested by doctors have been duly completed. Material transfer was done  
637 under a signed agreement (CNRS n° 227232, CHU n° 20 427 C). This study was declared and  
638 approved by the governing body of the Toulouse University Hospital with the agreement  
639 number RnIPH 2021-99, confirming that ethical requirements were fully respected.

640

641 **Human samples**

642 The 60 whole blood samples were collected, regardless of gender, in the course of the  
643 month September 2021. Those were anonymized within 24 hours of collection, transferred  
644 from the hospital to the research lab, and kept at room temperature until being used for  
645 HAT assays within 24 hours (i.e. less than 48 hours after blood samples were collected). In  
646 trial experiments, we had found that such samples could be stored for up to 5 days without  
647 any noticeable difference in the performance of the HAT tests.

648

649 After the whole blood samples had been used for HAT-field assays, the tubes were then  
650 spun, the plasmas harvested into fresh tubes, and sodium azide added to 3 mM final. Those  
651 harvested plasmas were kept at 4°C until they were used to perform the Jurkat-S&R-flow  
652 tests and HAT assays for plasma titrations.

653

654 The identities, clinical conditions and Covid status (PCR or positive serology) were unknown  
655 to the person performing the HAT experiments and Jurkat-S&R-flow tests.

656

657 Blood samples from O- donors (6 ml EDTA tubes) were obtained every few weeks from the  
658 EFS (Toulouse blood bank). Whilst whole blood is best kept at room temperature (i.e.  
659 between 20 and 25 °C), and can then only be used for HAT assays for up to 5 or 6 days,  
660 washed red blood cells can be kept for several weeks, as long as they have been separated  
661 from the white blood cells, and are kept at 4°C in the right buffer (in our case Alsever's  
662 solution, Sigma A3551).

663

664 For preparing RBCs for storage at 4°C, we used the following standard protocol. The EDTA  
665 collection tube is spun at 1000g for 20 minutes with no refrigeration, and the centrifuge  
666 brake set to 2 /9. The plasma is collected into a separate sterile tube and a total of 8 ml of  
667 sterile PBS used to resuspend the cells and transfer them to a 15 ml tube, on top of a 3 ml  
668 cushion of lymphocyte separation medium ( Corning Ref 25-072-CV ). This tube is then spun  
669 once more at 1000g for 20 minutes with no refrigeration, and the centrifuge brake set to 2  
670 /9. The supernatant, including the ring of white blood cells, is aspirated and discarded. The  
671 RBC pellet is then washed twice with 8 ml sterile PBS, once in 8 ml Alsever's solution, before  
672 adding two volumes of Alsever's solution to the one volume of packed RBCs. This tube of  
673 RBCs (at 30% v/v) can then be stored at 4°C, and used for HAT assays for several weeks.  
674 After a week of storage, however, we found that the RBCs progressively tend to lose their  
675 capacity to teardrop after spinning.

676 If whole blood from an O- donor was needed for experiments (e.g. as in Figure 2), 100-200  $\mu$ l  
677 were transferred to a separate sterile tube before performing the above procedure, and this  
678 tube was kept at room temperature for a maximum of 4 days. Worthy of note, whilst all  
679 donors were seronegative at the start of this study (i.e. from summer 2020 to winter 2021,  
680 the proportion of seropositives started increasing in the spring 2021, correlating with the  
681 proportion of vaccinated people increasing in the French population, and we have come  
682 across no seronegative samples among the dozen of blood samples we have used since the  
683 beginning of the summer 2021. Whilst the serological status of the donors does not matter  
684 when working with washed RBCs, it would thus no longer be practical to plan performing  
685 HAT tests in the presence of 1% autologous plasma as originally recommended (Townsend  
686 et al. 2021), but, as shown in figure 1, this is no longer necessary in the presence of 1% BSA.  
687

### 688 **Original HAT assays**

689 For HAT assays performed under 'standard' original HAT conditions, outside of using PBN  
690 instead of PBS, we used similar reagent concentrations and incubation conditions to  
691 those defined in our original description of HAT (Townsend et al. 2021):

- 692 - in a final volume of 100  $\mu$ l per well
- 693 - with approximately 0.3  $\mu$ l of packed RBCs per well, i.e. 1  $\mu$ l of 30 % stock stored in  
694 Alsever's solution.
- 695 - using IH4-RBD at a final concentration of 1  $\mu$ g/ml (i.e. 100 ng/well), or alternatively 0.5  
696  $\mu$ g/ml of IH4 alone since the sequences of the nanobody and the His tag represent slightly  
697 less than half of the IH4-RBD recombinant protein.
- 698 - Taking pictures after incubating the plates for 60 minutes at room temperature, for which  
699 we find it very convenient to use a very simple home-made lightbox  
700 (<https://youtu.be/e5zBYd19nIA> ).

701  
702 For experiments such as that presented in Figure 1, tubes of the appropriate 2X stocks  
703 containing either the RBCs and the antibodies, or the IH4-RBD reagent were prepared to be  
704 mixed 50/50 in each well.

705  
706 For titration experiments, we prepared stocks containing RBCs and the appropriate amount  
707 of the reagent to be kept constant (either the IH4-RBD reagent at 1  $\mu$ g/ml or IH4 alone at 0.5  
708  $\mu$ g/ml for plasma titrations, or the appropriate antibody dilution for IH4-RBD titrations). 100  
709  $\mu$ l of those stocks were then distributed per well, and 200  $\mu$ l for the wells of the first row.  
710 The reagents to be titrated were then added to each of the wells of the first row, and a  
711 multi-channel pipet was then used perform the serial dilutions by successive transfer of 100  
712  $\mu$ l to the wells of the adjacent row, with thorough mixing by pipetting gently up and down at  
713 least 6 times at each diluting step.

714  
715 A similar method was used to perform the 2D titrations presented in figure 4, filling columns  
716 of wells with stocks of IH4-RBD serially diluted with the appropriate suspension of RBCs, and  
717 proceeding in a second stage to perform serial dilutions of the antibodies in rows, as  
718 described above.

719  
720

721 **HAT-field assays**

722 The optimized procedure we have arrived to and used for this study is based on using 7  
723 serial dilutions of the IH4-RBD reagent. Rather than double dilutions, we elected to use 3.16  
724 as a dilution factor between adjacent wells. This not only allows to cover a larger range of  
725 IH4-RBD concentrations, but because 3.16 is the square root of 10, two successive dilutions  
726 conveniently correspond to a factor of 10. The concentrations of the IH4-RBD stocks used to  
727 prefill the wells were thus, in ng/ml 4750, 1500, 475, 150, 47, 15, 4.7. After addition of one  
728 drop of diluted blood, i.e. roughly 30  $\mu$ l, the final volume was thus ca. 90  $\mu$ l, and the  
729 approximate final concentrations of IH4-RBD in the wells were thus, in ng/ml: 3160, 1000,  
730 316, 100, 31, 10, 3.1.

731  
732 A detailed step by step protocol on how to generate the stocks of those various dilutions,  
733 and how to perform the HAT-field test, is provided as supplementary material.

734  
735 For every sample, the eighth well of a row is allocated to performing the very important  
736 negative control, which can consist of either PBN, or preferably PBN containing the IH4  
737 alone, i.e. the nanobody without the RBD attached to it, at 1.6  $\mu$ g/ml final concentration,  
738 corresponding to a molar concentration similar to that found in the well with the highest  
739 concentration of IH4-RBD.

740  
741 For the 60 samples of the cohort used in our study, because we were running sets of parallel  
742 HAT-field assays with either the IH4-RBD-Wuhan or IH4-RBD-Delta reagents, we performed  
743 both types of negative controls by using PBN as a negative control in the plates for the  
744 Wuhan HAT-field assays, and IH4 alone as a negative control in the plates for the Delta HAT-  
745 field assays. As discussed above, we found that the negative controls using the IH4 alone  
746 were much more informative.

747  
748 **Jurkat-S&R-flow**

749 Briefly, Jurkat-S and Jurkat-R cell lines, obtained and grown as previously described (Maurel  
750 Ribes et al. 2021), were resuspended in their own tissue culture medium at a concentration  
751 of  $2.2 \cdot 10^6$  cells/ mL before pooling equal volumes of the two.

752  
753 Plasmas to be tested were diluted 1/10 in PFN (PBS / 2% FCS / 200 mg/L sodium azide ). 20  
754  $\mu$ L of these 1/10 dilutions were then placed in U-bottom 96 well plates, before adding 180  $\mu$ l  
755 per well of the Jurkat-S&R mix.

756  
757 The plates were then incubated for 30 minutes at room temperature before placing them on  
758 ice for a further 30 minutes. All subsequent steps were carried out in the cold, with plates  
759 and washing buffers kept on ice. After the primary staining, samples were washed in PFN,  
760 with resuspending the cells by tapping the plate after each centrifugation, before adding 150  
761  $\mu$ l of PFN for the next wash. After 2 washes, the samples were split into 4 wells, and all  
762 resulting samples were washed one last time.

763  
764

765 One drop (i.e. ca. 30  $\mu$ l) of either the pan-specific anti-Ig-GAM secondary fluorescent  
766 antibodies, as well as anti-IgG, -IgA or -IgM, all diluted 1/200 in PFN was added to each of  
767 the four wells for each sample, and the cells resuspended by gentle shaking of the  
768 plates. After an incubation of 60 min on ice, samples were washed two more times with cold  
769 PFN before transferring the samples to acquisition tubes in a final volume of 300  $\mu$ l PFN  
770 containing 30 nM TO-PRO™-3 Iodide (Thermo Fischer Scientific, ref T3605).

771  
772 The samples were then analyzed on a FACScalibur flow cytometer controlled by the  
773 Cellquest pro software (Version 5.2, Beckton Dickinson), using the FL1 channel for Alexa-488,  
774 the FL3 channel for m-Cherry, and the FL4 channel (with the 633 nm laser) for live gating  
775 with the TO-PRO™-3 live stain. Post-acquisition analysis of all the samples was performed  
776 using the Flowjo software (version 10.7.1). The values used as results are those for specific  
777 staining, i.e. the difference between the GMFI (geometric mean fluorescent index )  
778 measured on the Jurkat cells expressing the SARS-CoV-2 spike protein and the control Jurkat  
779 cells expressing the mCherry fluorescent protein. The value of 40 of specific staining was  
780 used as the threshold above which the samples were considered as positive. As described  
781 previously, with the cytometer settings used in this study, this correspond to 20 fold the  
782 value obtained with cells stained just with the secondary antibody (Maurel Ribes et al. 2021).

783

#### 784 **FACS analysis of RBCs after HAT**

785 To quantify the amount of antibodies bound to the RBCs' surface after a HAT assay, an  
786 adjustable pipet was used to resuspend the RBCs by pipetting up and down several times,  
787 and 15  $\mu$ l (out of 90 or 100 ) were transferred to the well of a U-bottom 96 well plate pre-  
788 filled with 150  $\mu$ l PFN. The RBCs were then washed by three repeated sequences of  
789 centrifugation at 800 g for 3 min, followed by flicking the supernatant out, tapping the plate,  
790 and adding 150  $\mu$ l of PFN. One drop (i.e. ca. 30  $\mu$ l) of anti-human secondary antibody  
791 conjugated to alexa-488, diluted 1/200 in PFN was added to each of the wells, and the cells  
792 resuspended by gentle shaking of the plates. After an incubation of 60 min on ice, samples  
793 were washed two more times with cold PFN before transferring the samples to acquisition  
794 tubes in a final volume of 300  $\mu$ l PFN. The samples were then analyzed on a FACScalibur flow  
795 cytometer controlled by the Cellquest pro software (Version 5.2, Beckton Dickinson). Post-  
796 acquisition analysis of all the samples was performed using the Flowjo software (version  
797 10.7.1)

798

799 Because they can be obtained in very large numbers and stored at 4°C for several weeks, it is  
800 actually much simpler to use RBCs for FACS analysis than Jurkat cells, which need to be kept  
801 in culture continuously. But we find that FACS analysis of RBCs has a much reduced dynamic  
802 range compared to the Jurkat-S&R-flow test. It is indeed less sensitive, and many samples  
803 harboring low levels of antibodies would not be detected by RBC staining. And for samples  
804 that contain very high amounts of antibodies, the RBCs will tend to stay agglutinated, and  
805 the resulting cell clumps will be discounted during FACS analyses, with samples containing  
806 much lower numbers of usable cells, and the FACS results skewed towards lower values. If  
807 wanting to perform FACS analysis of RBCs after HAT, a solution to avoid this problem of  
808 clumping is to analyze those samples that are just one or two dilutions above the endpoint.  
809 But this will mean that all samples will not all have been stained with the same amounts of  
810 reagent and consequently that the staining levels cannot be compared with one another.

811 Alternatively, the problem can also be avoided by keeping the concentrations of the IH4-RBD  
812 below 100 ng/ml, but this will result in a further reduction of the sensitivity for the samples  
813 with low levels of antibodies.

814

#### 815 **Author contributions**

816

Name	First name	ORCID	contributions
Joly	Etienne	<a href="https://orcid.org/0000-0002-7264-2681">0000-0002-7264-2681</a>	Designed and funded the study; Performed the experiments; Wrote the paper.
Maurel Ribes	Agnes	<a href="https://orcid.org/0000-0002-7560-9502">0000-0002-7560-9502</a>	Collected and anonymized blood samples.

817

#### 818 **Other contributors**

819

Townsend	Alain	Designed the IH4-RBD reagents and funded their production. Established the initial HAT protocol
Tiong	Tan	Produced the IH4-RBD reagents
Rijal	Pramilla	Produced the IH4-RBD reagents
Featherstone	Carol	Copy edited parts of the manuscript

820

#### 821 **Funding**

822 This project was initially funded by a private donation, and subsequently by the ANR grant  
823 HAT-field to EJ.

824

#### 825 **Acknowledgements**

826 We are particularly grateful to the following people: Alain Townsend, Tiong Kit Tan, Pramila  
827 Rijal, who contributed the various materials detailed in the above table, and to Carol  
828 Featherstone for copy editing. We also gratefully acknowledge the contributions of  
829 Marianne Navarra, for her help in setting up the agreement with the hospital; Emmanuelle  
830 Naser and Pénélope Viana from the IPBS flow cytometry facility for their assistance; the staff  
831 of the Toulouse EFS (Etablissement Français du Sang) for the provision of O- blood samples;  
832 Florence Abravanel and Jacques Izopet for providing immune sera from convalescent Covid  
833 patients, and Eric Vallée for the experiments he carried out very early on in the course of the  
834 pandemic to compare the performance of HAT with those of the lateral flow assays.

835 **Supplementary material:**

836

837 1) **Data file for the clinical samples:** With the cohort of 60 clinical samples of whole

838 blood we used to validate the performance of the modified HAT protocols, we ended

839 up producing 24 different sets of data. Whilst a good number of different

840 comparisons between those sets are presented on figures 6 and S1-3, it was not

841 practical to provide comparisons for all the possibly interesting combinations. With

842 the sets of data provided as an Excel file, interested reader wanting to explore other

843 comparisons not provided here can easily perform those.

844

845 The data sets provided are as follows:

846

Column	
A	Sample numbers
<b>HAT-field scores</b> (starting with IH4-RBD at 3.16 µg/ml) Each score increment corresponds to dilution of IH4-RBD by a factor of 3.16	
B	IH4-RBD Wuhan after 60' under normal gravity
C	IH4-RBD Wuhan after 60' + 1' spin @ 100g
D	IH4-RBD Delta after 60' under normal gravity
E	IH4-RBD Delta after 60' + 1' spin @ 100g
F	IH4-RBD Wuhan 1' spin @ 100g after 15' incubation
G	IH4-RBD Delta 1' spin @ 100g after 15' incubation
H	IH4-RBD Wuhan after 1 hour under normal gravity
I	IH4-RBD Wuhan after 3 hours under normal gravity
J	IH4-RBD Wuhan after 5 hours under normal gravity
K	IH4-RBD Delta after 1 hour under normal gravity
L	IH4-RBD Delta after 3 hours under normal gravity
M	IH4-RBD Delta after 5 hours under normal gravity
<b>Titration on O- RBCs</b> (using 1 µg/ml IH4-RBD) Starting with plasmas @1/50 (score 1) Each score increment corresponds to one further double dilution of plasma	
N	IH4-RBD Wuhan after 60' under normal gravity
O	IH4-RBD Wuhan after 60' + 1' spin @ 100g
P	IH4-RBD Delta after 60' under normal gravity
Q	IH4-RBD Delta after 60' + 1' spin @ 100g
<b>Reactivities on IH4 alone</b> (performed only on those samples which had shown reactivity on IH4 alone @ 1.6 µg/ml ) in the initial whole blood screen	
<b>HAT-field scores</b> (starting with IH4 alone at 1.6 µg/ml) Each score increment corresponds to dilution of IH4 alone by a factor of 3.16	
R	IH4 alone after 60' under normal gravity
S	IH4 alone after 60' under normal gravity + 1' spin @ 100g
<b>Titration on O- RBCs</b> (using 0.5 µg/ml IH4 alone) Starting with plasmas @1/50 (score 1) Each score increment corresponds to one further double dilution of plasma	
T	IH4 alone after 60' under normal gravity
U	IH4 alone after 60' under normal gravity + 1' spin @ 100g
<b>Results of the Jurkat-S&amp;R-flow test</b> (GMFI Jurkat-S – GMFI Jurkat-R )	

V	All human Igs: ( red scale was applied to symbolize signal intensities )
W	IgG ( blue scale was applied to symbolize signal intensities )
X	IgA ( yellow scale was applied to symbolize signal intensities )
Y	IgM ( green scale was applied to symbolize signal intensities )
Comparison of the signals obtained for IgG / IgA / IgM (bar for negative samples)	
Z	Sums of columns W (IgG) + X ( IgA) + Y (IgM)
AA	Percentage of signal for IgG (blue scale)
AB	Percentage of signal for IgA (yellow scale)
AC	Percentage of signal for IgM (green scale)
<b>Clinical information</b>	
AD	Gender of patient
AE	Covid / PCR History

847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863

**2) Supplementary figures:**

Figure S1: Influence of the incubation times on HAT-field scores

Figure S2: Spinning of plates for plasma titrations after 60 minutes incubation under normal gravity also greatly increases sensitivity

Figure S3: Comparing scores obtained with IH4-RBD-delta to those obtained with IH4-RBD Wuhan

**3) Step by step protocol for HAT-field**

**4) Tutorial video on how to make a very simple lightbox.**

864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914

## Bibliography

- Ertesvåg, N.U., Xiao, J., Zhou, F., et al. 2021. A Rapid Antibody Screening Haemagglutination Test for Predicting Immunity to Sars CoV-2 Variants of Concern. *Research square*.
- Habib, I., Smolarek, D., Hattab, C., et al. 2013. V(H)H (nanobody) directed against human glycoporphin A: a tool for autologous red cell agglutination assays. *Analytical Biochemistry* 438(1), pp. 82–89.
- Jayathilaka, D., Jeewandara, C., Gomes, L., et al. 2021. Comparison of kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222. *medRxiv*.
- Jeewandara, C., Guruge, D., Abyrathna, I.S., et al. 2021. Seroprevalence of SARS-CoV-2 Infection in the Colombo Municipality Region, Sri Lanka. *Frontiers in public health* 9, p. 724398.
- Jeewandara, C., Kamaladasa, A., Pushpakumara, P.D., et al. 2021. Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers. *Nature Communications* 12(1), p. 4617.
- Kemp, B.E., Rylatt, D.B., Bundesen, P.G., et al. 1988. Autologous red cell agglutination assay for HIV-1 antibodies: simplified test with whole blood. *Science* 241(4871), pp. 1352–1354.
- Kenny, G.E. and Dunsmoor, C.L. 1983. Principles, problems, and strategies in the use of antigenic mixtures for the enzyme-linked immunosorbent assay. *Journal of Clinical Microbiology* 17(4), pp. 655–665.
- Kruse, R.L., Huang, Y., Lee, A., et al. 2021. A Hemagglutination-Based Semiquantitative Test for Point-of-Care Determination of SARS-CoV-2 Antibody Levels. *Journal of Clinical Microbiology* 59(12), p. e0118621.
- Lamikanra, A., Nguyen, D., Simmonds, P., et al. 2021. Comparability of six different immunoassays measuring SARS-CoV-2 antibodies with neutralising antibody levels in convalescent plasma: from utility to prediction. *Transfusion*.
- Maurel Ribes, A., Bessiere, P., Guery, J.-C., et al. 2021. A simple, sensitive and quantitative FACS-based test for SARS-CoV-2 serology in humans and animals. *medRxiv*.
- ter Meulen, J., van den Brink, E.N., Poon, L.L.M., et al. 2006. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. *PLoS Medicine* 3(7), p. e237.
- Redecke, V., Tawaratsumida, K., Larragoite, E.T., et al. 2021. A rapid and affordable point of care test for antibodies against SARS-CoV-2 based on hemagglutination and artificial intelligence interpretation. *Scientific Reports* 11(1), p. 24507.
- Townsend, A., Rijal, P., Xiao, J., et al. 2021. A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. *Nature Communications* 12(1), p. 1951.
- Wegmann, T.G. and Smithies, O. 1966. A simple hemagglutination system requiring small amounts of red cells and antibodies. *Transfusion* 6(1), pp. 67–73.
- Wegmann, T.G. and Smithies, O. 1968. Improvement of the microtiter hemagglutination method. *Transfusion* 8(1), p. 47.
- Wilson, K.M., Gerometta, M., Rylatt, D.B., et al. 1991. Rapid whole blood assay for HIV-1 seropositivity using an Fab-peptide conjugate. *Journal of Immunological Methods* 138(1), pp. 111–119.
- Zhou, D., Duyvesteyn, H.M.E., Chen, C.-P., et al. 2020. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. *Nature Structural & Molecular Biology* 27(10), pp. 950–958.